Key result
Long-term mexiletine treatment in patients with non-dystrophic myotonias was safe with no cardiac arrhythmias, though 22% of patients discontinued therapy primarily due to dyspepsia or other reasons.
Why the study?
The study was conducted to evaluate the long-term efficacy and safety of mexiletine in patients affected by genetically confirmed non-dystrophic myotonias.
Cohort (n=112)
Yes
Long-term use of mexiletine in patients with non-dystrophic myotonias is safe and effective, with no cardiac arrhythmias observed and dyspepsia being the primary dose-limiting side effect.
Answers are grounded in this paper and cite their sources.
May support mexiletine in selected non-dystrophic myotonias; leaves open need for randomized confirmation.
Objective: The aim of our study was to evaluate long-term efficacy and safety of mexiletine in 112 patients affected by genetically confirmed non-dystrophic myotonias. The study was performed at the Neurophysiologic Division of Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome and the Children’s Hospital Bambino Gesù, Rome. Methods: The treatment was accepted by 59 patients, according to clinical severity, individual needs, and concerns about a chronic medication. Forty-three patients were affected by recessive congenita myotonia, 11 by sodium channel myotonia, and 5 by dominant congenital myotonia. They underwent clinical examination, before and after starting therapy, and EMG. A number of recessive myotonia patients underwent a protocol of repetitive nerve stimulations, for detecting and quantifying the transitory weakness, and a modified version of the Timed Up and Go test, to document and quantify the gait impairment. Results: Treatment duration ranged from 1 month to 20 years and the daily dosages in adults ranged between 200 and 600 mg. No patient developed cardiac arrhythmias causing drug discontinuation. Mexiletine was suspended in 13 cases (22%); in 3 patients, affected by Sodium Channel myotonia, because flecainide showed better efficacy; in 1 patient because of a gastric cancer antecedent the treatment; in 4 patients because of untreatable dyspepsia; 5 patients considered the treatment not necessary. Conclusions: In our experience, mexiletine is very useful and not expensive. We did not observe any hazarding cardiac arrhythmias. Dyspepsia was the most frequent dose-limiting side effect.
No takes yet. Share an insight, caveat, or question.
Modoni et al. (2020) conducted a cohort in Non-dystrophic myotonias (n=112). Mexiletine vs. Untreated patients was evaluated on Drug discontinuation. Long-term mexiletine treatment in patients with non-dystrophic myotonias was safe with no cardiac arrhythmias, though 22% of patients discontinued therapy primarily due to dyspepsia or other reasons.
Synapse has enriched 10 related papers. Consider them for comparative context: